15018752330
发表时间:2015-11-24 浏览次数:455次
It is my privilege to introduce the second issue of the Journal of
Cancer Metastasis and Treatment. In keeping with the format we have
chosen for our journal, this issue contains two reviews focusing on
fields of great translational and clinical interest, five original
articles, and three case reports. The first review discusses the rapidly
evolving field of circulating tumor cells (CTC) as cancer biomarkers.
Since the introduction of the first Food and Drug Administration
approved CTC test to assess the progression of metastatic breast,
colorectal and prostate cancer, CTC have generated tremendous interest
among clinicians seeking sensitive progression biomarkers and basic
scientists interested in isolating and studying these cells. A number of
new sorting, capture, and enumeration technologies are being evaluated.
Competing technologies have emerged, such as circulating tumor DNA. The
review by Potdar and Lotey summarizes the current experience with CTC
as diagnostic and prognostic biomarkers and the future of this
technology. The review by Alfonso et al. describes recent
progress in our understanding of urothelial cancer, a poorly understood
malignancy that can be very difficult to treat, based on novel
translational science. The original articles cover a variety of
translational and clinical topics: the rapidly growing field of
extracellular microRNA (miRNA) detection and quantification, as applied
to medulloblastoma; the management of diffuse large B-cell non-Hodgkin
lymphoma (NHL) in elderly Egyptian patients; the prognostic value of
GATA3 and FOXA1 detection in breast cancer; current clinical criteria
for the management of squamous non-small cell lung cancer (NSCLC); and
the pharmacological properties of Withania somnifera extract in a
triple-negative breast cancer model. miRNAs and other non-coding RNAs
in biological fluids promise to revolutionize the world of biomarkers.
However, there remain significant technical issues surrounding the
reproducible quantification of miRNAs for clinical purposes. The
manuscript by Shalaby et al. is an example of progress in this highly promising field. The manuscript by Zeeneldin et al.
describes the experience of treating diffuse large B-cell NHL in a
geriatric setting where safety and efficacy considerations have be
balanced against each other and where monoclonal antibodies are not
always available. The study by Chivukula et al. proposes the
intriguing hypothesis that immunohistochemical detection of the
transcription factor GATA3 and "pioneer" factor FOXA1 has prognostic
value in breast cancer. The manuscript by Savini et al. describes
the experience of this group treating squamous NSCLC, analyzing
variables associated with improved survival in their patient population.
The article by Ray et al. describes the effect of a promising natural product, an extract from well-known medicinal plant Withania somnifera,
on the production of cytokines associated with metastasis in a standard
triple-negative breast cancer model. Finally, the three case reports
describe unusual presentations, including histologically different
metastases from an unknown primary lesion, orbital metastasis from
rectal carcinoma and a mature spinal teratoma presenting in an elderly
patient.
I hope you enjoy reading this issue, and the ones that will follow.